Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2001 / Cilt: 27 - Sayı: 4

Is prostate specific antigen in the patients with primary prostate cancer diagnosed with bone scintigraphy?

Prostat kanserli hastalarda prostat spesifik antijen (PSA) kemik metastazlarının belirleyicisi midir?

Pages
433–436
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For that reason, it is appropriate that all patients with PCa should undergo baseline bone evaluation regardless PSA levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Digital rectal examination (DRE), serum prostate specific antigen (PSA) levels and bone scintigrahy in patients with prostate cancer are the staging tools used the most common.
📊
Key Findings & Data:The patients were divided into 2 groups according to scintigraphy results as positive and negative.
💡
Conclusion & Impact:For that reason, it is appropriate that all patients with PCa should undergo baseline bone evaluation regardless PSA levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Prostat neoplazmları · Prostata özgü antijen · Kemik hastalıkları

Abstract

Digital rectal examination (DRE), serum prostate specific antigen (PSA) levels and bone scintigrahy in patients with prostate cancer are the staging tools used the most common. In this study, it has been investigated whether there is any relationship between serum PSA levels and bone scintigraphy in the patients diagnosed with prostate cancer (PCa). Ninety-nine patients with PCa were included. The patients were divided into 2 groups according to scintigraphy results as positive and negative. The difference between the groups regarding the patients' age and serum PSA levels was evaluated by Student-t test. No bone involvement in scintigraphy was found in 38 patients while 61 patients had bone involvement. PSA level was 93.12$\pm$9.66 ng/ml in patients with bone involvement while it was 31.95 ±4.10 ng/ml in those without bone involvement. There was a significantly difference between both groups in terms of serum PSA levels. All of the patients with PSA levels above 100 ng/ml (n:22) had bone involvement. Six of 22 patients with serum PSA levels less than 20 ng/ml (9.8%) had bone involvement. High PSA levels are a good marker for bone involvement. However, approximately 10% of the patients with low PSA levels (n:22) may be found bone involvement, as well. For that reason, it is appropriate that all patients with PCa should undergo baseline bone evaluation regardless PSA levels.

Özet

Prostat kanseri (PCa) olan hastalarda parmakla rektal muayene (PRM), serum PSA düzeyleri ve kemik sintigrafisi en sık kullanılan evreleme yöntemleridir. Bu çalışmada, PCa tanısı almış hastalarda prostat spesifik antijen (PSA) düzeyleri ile kemik sintigrafisi arasında bir ilişki olup olmadığı araştırıldı. Prostat kanseri tanısı konmuş 99 hasta çalışmaya dahil edildi. Bu hastalar kemik sintigrafi sonuçlarına göre sintigrafi pozitif ve negatif olarak 2 gruba ayrıldı. Hasta yaşı ve serum PSA düzeyleri açısından gruplar arasındaki fark Student-t testi ile değerlendirildi. Altmış bir hastada (%61,6) sintigrafik olarak kemik tutulumu saptanırken, 38 hastada (%38,4) sintigrafik olarak kemik tutulumu yoktu. Kemik tutulumu saptanan hastalarda PSA düzeyi 93.12±9.66 ng/ml iken kemik tutulumu olmayanlarda PSA düzeyi 31.95±4.10 ng/ml olarak bulundu. Her iki grup arasında da PSA düzeyleri açısından anlamlı fark vardı (p=0.0000, p<0,05). PSA düzeyi 100 ng/ml üzeri olan tüm hastalarda (n=22) kemik tutulumu vardı. PSA düzeyi 20 ng/ml altında olan 22 hastanın ise 6'sında (%9.8) kemik tutulumu saptandı. Sonuç olarak yüksek PSA değerleri kemik tutulumunun iyi bir belirleyicisidir. Ancak PSA düzeyi düşük olan prostat kanserli hastalarda da yaklaşık olarak %10 oranında kemik tutulumu bulunabilmektedir. Bu nedenle PSA düzeyine bakılmaksızın prostat kanseri tanısı konmuş tüm hastaların bazal kemik değerlendirmelerinin yapılması uygun olacaktır.

🔖

Cite This Article

TEKDOĞAN, Ü. Y., ORTAPAMUK, H., OĞUZ, E., BAŞAR, M. M., NALDÖKEN, S., ATAN, A. (2001). Is prostate specific antigen in the patients with primary prostate cancer diagnosed with bone scintigraphy?. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 27 - Sayı: 4, 433–436. https://ajindex.com/articles/328886

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Wolff JM, Zimny M, Borchers H, et al: Is pros-tate specific antigen a reliable marker of bone metastasis in patients with newly diagnosed can-cer of the prostate? Eur Urol. 33: 376-81,1998
  2. Haukaas S, Roervik J, Halvorsen OJ, et al: When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prosta-te cancer? Br J Urol. 79: 770-76, 1997
  3. Pantelides ML, Bowman PS, George NJ: Le-vels of PSA that predict skeletal spread in prosta-te cancer. Br J Urol 70: 299-303, 1992
  4. Oesterling JE: Using prostate-specific antigen to eliminate unnecessary diagnostic tests; significant worldwide economic implications. Urology. 46: 26-33, 1995
  5. Larente JA, Valenzuela H, Morote J, et al: Se-rum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer pati-ents. Eur J Nucl Med 26: 625-32, 1999
  6. Oesterling JE: Using PSA to eliminate the sta-ging radionuclide bone scan. Significant economic implications. Urol Clin Notrh Am 20: 705-11, 1993
  7. Rudoni M, Antonini G, Favro M, et al: The cli-nical of prostate specific antigen and bone scinti-graphy in the staging of patients with newly diag-nosed, pathologically proven prostate cancer. Eur J Nucl Med 22: 207-11, 1995
  8. Paresti JC: Neoplasm of the prostate gland. Ta-nagho EA, Mc Aninch JW (eds) Smith”s General Urology. 15th Edition. The Mc Graw Hill, New York, 2000, pp: 399-421
  9. Lee CT, Oesterling JE: Using PSA to eliminate to staging radionuclide bone scan. Urol Clin North Am.24: 389-94, 1997
  10. Chybowski FM, Keller JJ, Bergstrahl EJ, et al: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other parameters. J Urol 145: 313-8, 1991
  11. Kemp PM, Maguire GA, Bird UJ: Which pati-ents with protatic carsinoma require a staging bo-ne scan? Br J Urol 79: 611-4, 1997
  12. Bruwer G, Heyns CF, Allen FJ: Influence of lo-cal tumor stage and grade on reliability of serum prostate specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol. 35: 223-7, 1999
  13. Miller PD, Eardley I, Kırby RS: Prostate Speci-fic Antigen and bone scan correlation in the sta-ging and monitoring of patients with Prostatic cancer. Br J Urol 70: 295-98, 1992
  14. Wolff JM, Bares R, Jung PK et al: PSA as a marker of bone metastases in patients with pros-tate cancer. Urol Int 56: 169-73, 1996.